Literature DB >> 7883953

Hereditary porcine membranoproliferative glomerulonephritis type II is caused by factor H deficiency.

K Høgåsen1, J H Jansen, T E Mollnes, J Hovdenes, M Harboe.   

Abstract

We have recently described hereditary membranoproliferative glomerulonephritis type II in the pig. All affected animals had excessive complement activation, revealed as low plasma C3, elevated plasma terminal complement complex, and massive deposits of complement in the renal glomeruli, and eventually died of renal failure within 11 wk of birth. The aim of the present study was to investigate the cause of complement activation in this disease. Transfusion of normal porcine plasma to affected piglets inhibited complement activation and increased survival. Plasma was successively fractionated and the complement inhibitory effect of each fraction tested in vivo. A single chain 150-kD protein which showed the same complement inhibitory effect as whole plasma was finally isolated. Immunologic cross-reactivity, functional properties, and NH2-terminal sequence identified the protein as factor H. By Western blotting and enzyme immunoassay, membranoproliferative glomerulonephritis-affected piglets were demonstrated to be subtotally deficient in factor H. At 1 wk of age, median (range) factor H concentration was 1.6 mg/liter (1.1-2.3) in deficient animals (n = 13) and 51 mg/liter (26-98) in healthy littermates (n = 52). Our data show that hereditary porcine membrano-proliferative glomerulonephritis type II is caused by factor H deficiency.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7883953      PMCID: PMC441440          DOI: 10.1172/JCI117751

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  33 in total

1.  Modulation of C3b hemolytic activity by a plasma protein distinct from C3b inactivator.

Authors:  K Whaley; S Ruddy
Journal:  Science       Date:  1976-09-10       Impact factor: 47.728

2.  Idiopathic membranoproliferative glomerulonephritis in children. Report of 105 cases.

Authors:  R Habib; C Kleinknecht; M C Gubler; M Levy
Journal:  Clin Nephrol       Date:  1973 Jul-Aug       Impact factor: 0.975

3.  Porcine membranoproliferative glomerulonephritis with intramembranous dense deposits (porcine dense deposit disease).

Authors:  J H Jansen
Journal:  APMIS       Date:  1993-04       Impact factor: 3.205

4.  C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase.

Authors:  M R Daha; D T Fearon; K F Austen
Journal:  J Immunol       Date:  1976-01       Impact factor: 5.422

5.  Metabolism of human beta 1H: studies in man and experimental animals.

Authors:  J A Charlesworth; D M Scott; B A Pussell; D K Peters
Journal:  Clin Exp Immunol       Date:  1979-12       Impact factor: 4.330

Review 6.  Complement factor H and related proteins: an expanding family of complement-regulatory proteins?

Authors:  P F Zipfel; C Skerka
Journal:  Immunol Today       Date:  1994-03

7.  Renal lesions in Norwegian slaughter pigs. Macroscopic and light microscopic studies.

Authors:  J H Jansen; K Nordstoga
Journal:  Zentralbl Veterinarmed A       Date:  1992-10

8.  Control of the amplification convertase of complement by the plasma protein beta1H.

Authors:  J M Weiler; M R Daha; K F Austen; D T Fearon
Journal:  Proc Natl Acad Sci U S A       Date:  1976-09       Impact factor: 11.205

9.  Membranoproliferative glomerulonephritis with disruption of the glomerular basement membrane.

Authors:  C F Strife; P T McEnery; A J McAdams; C D West
Journal:  Clin Nephrol       Date:  1977-02       Impact factor: 0.975

10.  Modulation of the alternative complement pathways by beta 1 H globulin.

Authors:  K Whaley; S Ruddy
Journal:  J Exp Med       Date:  1976-11-02       Impact factor: 14.307

View more
  50 in total

Review 1.  Complement deficiency.

Authors:  K M O'Neil
Journal:  Clin Rev Allergy Immunol       Date:  2000-10       Impact factor: 8.667

2.  The molecular basis for hereditary porcine membranoproliferative glomerulonephritis type II: point mutations in the factor H coding sequence block protein secretion.

Authors:  Guido A Hegasy; Tamara Manuelian; Kolbjorn Hogasen; Johan H Jansen; Peter F Zipfel
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

Review 3.  Complement control protein factor H: the good, the bad, and the inadequate.

Authors:  Viviana P Ferreira; Michael K Pangburn; Claudio Cortés
Journal:  Mol Immunol       Date:  2010-08       Impact factor: 4.407

4.  Membranoproliferative glomerulonephritis with C3NeF and genetic complement dysregulation.

Authors:  Valérie Leroy; Véronique Fremeaux-Bacchi; Michel Peuchmaur; Véronique Baudouin; Georges Deschênes; Marie-Alice Macher; Chantal Loirat
Journal:  Pediatr Nephrol       Date:  2010-12-25       Impact factor: 3.714

5.  Properdin homeostasis requires turnover of the alternative complement pathway.

Authors:  Xiaobo Wu; Thomas Q Xu; John P Atkinson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-25       Impact factor: 11.205

Review 6.  Review: Complement and its regulatory proteins in kidney diseases.

Authors:  Allison M Lesher; Wen-Chao Song
Journal:  Nephrology (Carlton)       Date:  2010-10       Impact factor: 2.506

Review 7.  Clinical immunology.

Authors:  T E Mollnes; M Harboe
Journal:  BMJ       Date:  1996-06-08

8.  Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice.

Authors:  Fadi Fakhouri; Elena Goicoechea de Jorge; Frédérique Brune; Philippe Azam; H Terence Cook; Matthew C Pickering
Journal:  Kidney Int       Date:  2010-05-05       Impact factor: 10.612

9.  Pig complement regulator factor H: molecular cloning and functional characterization.

Authors:  Guido A Hegasy; Ute Willhoeft; Sandra A Majno; Harald Seeberger; Peter F Zipfel; Jens Hellwage
Journal:  Immunogenetics       Date:  2003-09-27       Impact factor: 2.846

10.  Novel targets for immunotherapy in glomerulonephritis.

Authors:  Mary H Foster
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.